Syndicated News

This blog is still in BETA

We are aware of any formatting errors. These stories are automatically pulled from RSS feeds. Due to the automated nature of the post, some images may appear small, and some links may not be clickable until our staff has had the opportunity to manicure the postings. Thank you for understanding.

March 13, 2015

Baxter (BAX) Phase III Study of BAX 817 Met Primary Endpoint - StreetInsider.com

March 13, 2015/

http://ift.tt/1GMIxC5 Click to read full article...

Baxter (BAX) Phase III Study of BAX 817 Met Primary EndpointStreetInsider.comBaxter International Inc. (NYSE: BAX) today announced positive results from its Phase III clinical trial evaluating the safety and efficacy of BAX 817, an investigational recombinant factor VIIa (rFVIIa) treatment for people with hemophilia A or B who ...Baxter BioScience Announces Positive Phase III Results for BAX 817 ...MarketWatchall 5 news articles »

from Hemophilia - Google News http://ift.tt/1GMIxC5 via IFTTT

Committee of Ten Thousand

ADVOCATES FOR PERSONS WITH HIV/AIDS, HEMOPHILIA, HCV, AND SICKLE CELL

MONITORING THE BLOOD SUPPLY AND PROTECTING PATIENT RIGHTS SINCE 1989

The Committee of Ten Thousand is a grass-roots, peer-led, education, advocacy and support organization. The majority of our constituency is persons with hemophilia who contracted HIV/AIDS from tainted blood products. We work in solidarity with all communities affected by the HIV/AIDS pandemic. COTT advocates for disenfranchised chronic disease communities, especially those communities dependent on a safe national blood supply. We are dedicated to the belief that persons with HIV/AIDS and all chronic diseases can lead productive and healthy lives.

Syndicated News

Syndicated News Feed

Baxter (BAX) Phase III Study of BAX 817 Met Primary Endpoint - StreetInsider.com

Committee of Ten Thousand

Quick Links - Sections